立体定向心律失常放射消融治疗难治性室性心动过速的系统评价与荟萃分析
该系统评价与荟萃分析纳入22项研究共215例难治性单形性室性心动过速患者,评估立体定向心律失常放射消融(STAR)的疗效与安全性。结果显示随访期间总生存率69.6%,室速发作和ICD放电每月分别减少81.5%和84.7%,但仅23.1%患者无室速复发;352例不良事件中50.6%为严重,仅9.7%可能与STAR相关。
要点
- STAR可显著减少难治性室速患者的室速发作和ICD放电,但无室速复发率仅23.1%。
- 随访期间总生存率69.6%,不良事件中50.6%为严重,但仅9.7%可能与STAR相关。
- 前瞻性与回顾性研究、高与低计划靶区体积亚组间临床结局无显著差异。
核心结论
- STAR显著减少室速发作和ICD放电,提供症状缓解,但高复发率和严重不良事件提示需优化方案和多学科协作。
研究设计与样本
- 系统评价与荟萃分析,遵循PRISMA和MOOSE指南,检索MEDLINE和EMBASE至2024年6月30日。
- 荟萃分析仅纳入前瞻性和回顾性研究,共22项研究215例患者,年龄66.0±4.4岁,85.9%为男性,左心室射血分数29.8±5.0%,52.2%为缺血性心肌病,平均随访11.9±6.6个月。
- 采用随机效应模型和双反正弦变换,按研究设计和计划靶区体积进行亚组分析。
主要发现
- 总生存率为69.6%(95%CI 62.6%至76.2%)。
- 室速发作和ICD放电每月分别减少81.5%(95%CI 64.2%至94.8%)和84.7%(95%CI 65.1%至98.1%)。
- 随访结束时仅23.1%(95%CI 10.7%至37.7%)患者无室速复发。
- 前瞻性与回顾性研究、高与低计划靶区体积亚组间临床结局无显著差异。
- 280例患者共报告352例不良事件,平均每例患者1.26例,其中50.6%为严重,仅9.7%可能与STAR相关。
临床怎么用
- STAR可作为难治性室速患者的非侵入性治疗选择,显著减少室速发作和ICD放电。
- 需关注高复发率和严重不良事件,治疗决策应结合多学科评估和个体化方案优化。
局限性
- 纳入研究以观察性研究为主,可能存在异质性和偏倚。
- 不良事件因果关系判定有限,仅9.7%可能与STAR相关。
- 随访时间平均11.9个月,长期疗效和安全性尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stereotactic arrhythmia radioablation (STAR) is a novel, non-invasive treatment for therapy-refractory ventricular tachycardia (VT). In STAR, a high dose of radiation is used to non-invasively target and treat the VT substrate. Initial studies indicate promising VT burden reduction, but comprehensive efficacy and safety evaluations remain limited. METHODS: A systematic review (Preferred Reporting Items for Systematic Reviews and Meta-Analyses/Meta-analysis Of Observational Studies in Epidemiology guidelines) included studies on STAR for monomorphic VT identified up to 30 June 2024 via MEDLINE and EMBASE. Outcomes assessed were freedom of VT, percentage reduction in VT episodes and implantable cardioverter-defibrillator (ICD) shocks per month, survival and adverse events (AEs). Meta-analyses included prospective and retrospective studies only, using random-effects models with double arcsine transformation. Subgroup analyses by study design and planning target volume (PTV) were performed. AEs were qualitatively analysed and classified by organ system, severity and causality. RESULTS: The meta-analysis included 215 patients from 22 studies (age 66.0±4.4 years, 85.9% men, left ventricular ejection fraction 29.8±5.0%, 52.2% ischaemic cardiomyopathy, mean follow-up of 11.9±6.6 months). The overall survival was 69.6% (95% CI 62.6% to 76.2%). VT episodes and ICD shocks/month reduced by 81.5% (95% CI 64.2% to 94.8%) and 84.7% (95% CI 65.1% to 98.1%), respectively. However, only 23.1% (95% CI 10.7% to 37.7%) were VT-free at the end of follow-up. There were no significant differences in clinical outcomes between prospective and retrospective studies, nor between studies with high PTV and low PTV. A total of 352 AEs were reported in 280 patients, with a mean of 1.26 AE per patient. Of these AEs, 50.6% were classified as severe, though only 9.7% were likely STAR-related. CONCLUSIONS: STAR significantly reduces VT episodes and ICD shocks, offering symptomatic relief. However, high recurrence rates and severe AEs underscore the need for protocol optimisation and multidisciplinary collaboration to improve STAR's safety and efficacy in VT management.
引用
- Goethals E, Vankelecom E, De Roover R, et al. Stereotactic arrhythmia radioablation in patients with refractory ventricular tachycardia: a systematic review and meta-analysis. Heart. 2026. PMID: 40633941. doi:10.1136/heartjnl-2025-325805
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。